The FDA has approved Eli Lilly’s Inluriyo (imlunestrant), an innovative oral estrogen receptor degrader (SERD), for adults with advanced or metastatic, estrogen receptor-positive (ER+), HER2-negative breast cancer harboring ESR1 mutations. This approval applies specifically to patients whose cancer has progressed after at least one prior course of endocrine therapy.
In the pivotal phase 3 EMBER-3 trial, Inluriyo demonstrated a 38% reduction in the risk of disease progression or death compared to standard endocrine therapies such as fulvestrant or exemestane. Median progression-free survival for patients on Inluriyo was 5.5 months versus 3.8 months for traditional therapy, highlighting a significant clinical benefit for a subgroup often resistant to existing hormone treatments.
The once-daily oral regimen is poised to replace injectables and provide new options for managing an aggressive subtype of breast cancer. While most side effects were low-grade, the drug does carry warnings for embryo-fetal toxicity and requires close physician oversight. Inluriyo is expected to become available in the U.S. within weeks, with ongoing trials exploring its broader use in early-stage disease. This advance marks a step forward for targeted, individualized breast cancer care.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!